Skip to content

Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer’s and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink

Research output: Contribution to journalArticle

Original languageEnglish
Article numbere012044
Number of pages10
JournalBMJ Open
Issue number12
Early online date13 Dec 2016
DateAccepted/In press - 20 Sep 2016
DateE-pub ahead of print - 13 Dec 2016
DatePublished (current) - Dec 2016


Introduction Current treatments for Alzheimer's and other neurodegenerative diseases have only limited effectiveness meaning that there is an urgent need for new medications that could influence disease incidence and progression. We will investigate the potential of a selection of commonly prescribed drugs, as a more efficient and cost-effective method of identifying new drugs for the prevention or treatment of Alzheimer's disease, non-Alzheimer's disease dementias, Parkinson's disease and amyotrophic lateral sclerosis. Our research will focus on drugs used for the treatment of hypertension, hypercholesterolaemia and type 2 diabetes, all of which have previously been identified as potentially cerebroprotective and have variable levels of preclinical evidence that suggest they may have beneficial effects for various aspects of dementia pathology.

Methods and analysis We will conduct a hypothesis testing observational cohort study using data from the Clinical Practice Research Datalink (CPRD). Our analysis will consider four statistical methods, which have different approaches for modelling confounding. These are multivariable adjusted Cox regression; propensity matched regression; instrumental variable analysis and marginal structural models. We will also use an intention-to-treat analysis, whereby we will define all exposures based on the first prescription observed in the database so that the target parameter is comparable to that estimated by a randomised controlled trial.

Ethics and dissemination This protocol has been approved by the CPRD's Independent Scientific Advisory Committee (ISAC). We will publish the results of the study as open-access peer-reviewed publications and disseminate findings through national and international conferences as are appropriate.

    Research areas

  • Alzheimer's disease, Neurodegenerative disease, Drug repurposing, Clinical Practice Research Datalink (CPRD), Pharmacoepidemiology

Download statistics

No data available



  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via BMJ Publishing Group at Please refer to any applicable terms of use of the publisher.

    Final published version, 899 KB, PDF document

    Licence: CC BY


View research connections

Related faculties, schools or groups